Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases.
14 patients with myeloproliferative diseases (MD) showed low 5-hydroxytryptamine (5-HT) platelet content and high beta-thromboglobulin (beta-TG) plasma levels. This pattern could support the view that MD platelets undergo "in vivo" degranulation. A single dose of aspirin was unable to induce modifications of platelet 5-HT and plasma beta-TG, whereas 6 out of 14 patients treated over 7 days period with the drug showed a decrease but not normalization in their beta-TG levels. No modification of platelet 5-HT was obtained suggesting that the cause of dense bodies deficiency may lie in the production of abnormal platelets and not be related to "in vivo" degranulation.
D000328:Adult; D000368:Aged; D001241:Aspirin / Q000494:pharmacology*; D001609:Beta-Globulins / Q000032:analysis*; D001792:Blood Platelets / Q000378:metabolism*; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000097:blood; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood*; D055728:Primary Myelofibrosis / Q000097:blood; D012701:Serotonin / Q000097:blood*; D001620:beta-Thromboglobulin / Q000032:analysis*
D001609:Beta-Globulins; D001620:beta-Thromboglobulin; D012701:Serotonin; D008315:Malondialdehyde; D001241:Aspirin